Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer.
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2015
At a glance
- Drugs Axitinib (Primary)
- Indications Adrenocortical carcinoma
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 26 Jun 2013 Primary endpoint amended as reported by ClinicalTrials.gov.
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Dec 2010 New trial record